Drugs and Drug Delivery for Diabetes Mellitus Treatment, 2nd Edition
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".
Deadline for manuscript submissions: 30 June 2024 | Viewed by 157
Special Issue Editors
Interests: retina; DME; AMD; uveitis; steroids; anti-VEGF
Special Issues, Collections and Topics in MDPI journals
Interests: retina; DME; AMD; oncology; steroids; anti-VEGF
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Diabetes is an epidemic disease with a prevalence that will double over the next 20 years. Diabetic macular oedema is the main cause of visual impairment in young people under 50. Screening for diabetic retinopathy is essential and is increasingly assisted by artificial intelligence. The classification of diabetic retinopathy is now quite old and must evolve, particularly with the help of OCT. Diagnosis has become multimodal. Numerous treatments exist, from anti-VEGF to steroids, with short- or long-acting molecules. The handling of these products is improving, and experience with them is growing. The results of observational studies sometimes differ a little or a lot from randomized controlled studies. Observational real-life studies are therefore becoming increasingly important in the medical world because they are relevant to our daily clinical practice. New treatments are also being considered.
Therefore, I wanted a Special Issue in Pharmaceutics to be quite open about the ophthalmological damage of diabetes, from diabetic retinopathy to diabetic macular oedema, more specifically dedicated to its therapeutic management. Indeed, I would like to receive original articles about new molecules with new drug molecular structures, new pathways of action, new mechanisms of action, new combination therapies or even biosimilars. Articles on short, medium or long delivery systems, such as implants, are welcome, especially on steroids, which are classical in DME management.
Prof. Dr. Laurent Kodjikian
Dr. Thibaud Mathis
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- diabetes
- diabetic macular edema (DME)
- diabetic
- retinopathy
- anti-VEGF to steroids
- molecular structures
- drug development
- drug targeting
- combination therapies
- delivery system
- implants
Related Special Issue
- Drugs and Drug Delivery for Diabetes Mellitus Treatment in Pharmaceutics (9 articles)
